CN110133290A - A kind of ELISA kit diagnosing heartworm disease - Google Patents
A kind of ELISA kit diagnosing heartworm disease Download PDFInfo
- Publication number
- CN110133290A CN110133290A CN201910469902.2A CN201910469902A CN110133290A CN 110133290 A CN110133290 A CN 110133290A CN 201910469902 A CN201910469902 A CN 201910469902A CN 110133290 A CN110133290 A CN 110133290A
- Authority
- CN
- China
- Prior art keywords
- elisa kit
- heat shock
- heart worm
- small heat
- shock protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000003917 Dirofilariasis Diseases 0.000 title claims abstract description 32
- 238000008157 ELISA kit Methods 0.000 title claims abstract description 19
- 241000002163 Mesapamea fractilinea Species 0.000 claims abstract description 42
- 102000008063 Small Heat-Shock Proteins Human genes 0.000 claims abstract description 22
- 108010088928 Small Heat-Shock Proteins Proteins 0.000 claims abstract description 20
- 239000007790 solid phase Substances 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 32
- 239000007788 liquid Substances 0.000 claims description 19
- 239000012895 dilution Substances 0.000 claims description 10
- 238000010790 dilution Methods 0.000 claims description 10
- 238000004140 cleaning Methods 0.000 claims description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 5
- 235000020183 skimmed milk Nutrition 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 abstract description 64
- 238000000034 method Methods 0.000 abstract description 31
- 239000000427 antigen Substances 0.000 abstract description 18
- 102000036639 antigens Human genes 0.000 abstract description 18
- 108091007433 antigens Proteins 0.000 abstract description 18
- 238000001514 detection method Methods 0.000 abstract description 15
- 238000002965 ELISA Methods 0.000 abstract description 14
- 238000002360 preparation method Methods 0.000 abstract description 11
- 208000015181 infectious disease Diseases 0.000 abstract description 8
- 230000005847 immunogenicity Effects 0.000 abstract description 7
- 238000002474 experimental method Methods 0.000 abstract description 3
- 230000001427 coherent effect Effects 0.000 abstract description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 29
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 21
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 21
- 241000894006 Bacteria Species 0.000 description 20
- 239000013612 plasmid Substances 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 12
- 230000029087 digestion Effects 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 230000006798 recombination Effects 0.000 description 7
- 238000005215 recombination Methods 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000004321 preservation Methods 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000009182 swimming Effects 0.000 description 5
- 241001147672 Ancylostoma caninum Species 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- 241000244030 Toxocara canis Species 0.000 description 4
- 230000037029 cross reaction Effects 0.000 description 4
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 4
- 238000003119 immunoblot Methods 0.000 description 4
- 230000009465 prokaryotic expression Effects 0.000 description 4
- 238000004064 recycling Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 201000003808 Cystic echinococcosis Diseases 0.000 description 3
- 241000244170 Echinococcus granulosus Species 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 239000006180 TBST buffer Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000005374 membrane filtration Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000001376 precipitating effect Effects 0.000 description 3
- 238000002331 protein detection Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 101150039504 6 gene Proteins 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 241000239183 Filaria Species 0.000 description 2
- 241000283977 Oryctolagus Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000009514 concussion Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 150000002460 imidazoles Chemical class 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 210000001147 pulmonary artery Anatomy 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 108091052270 small heat shock protein (HSP20) family Proteins 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- VCSABYLVNWQYQE-SRVKXCTJSA-N Ala-Lys-Lys Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CCCCN)C(O)=O VCSABYLVNWQYQE-SRVKXCTJSA-N 0.000 description 1
- VCSABYLVNWQYQE-UHFFFAOYSA-N Ala-Lys-Lys Natural products NCCCCC(NC(=O)C(N)C)C(=O)NC(CCCCN)C(O)=O VCSABYLVNWQYQE-UHFFFAOYSA-N 0.000 description 1
- 102100034613 Annexin A2 Human genes 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- 101100028789 Arabidopsis thaliana PBS1 gene Proteins 0.000 description 1
- JTZUZBADHGISJD-SRVKXCTJSA-N Arg-His-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(O)=O JTZUZBADHGISJD-SRVKXCTJSA-N 0.000 description 1
- NJIKKGUVGUBICV-ZLUOBGJFSA-N Asp-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O NJIKKGUVGUBICV-ZLUOBGJFSA-N 0.000 description 1
- UGKZHCBLMLSANF-CIUDSAMLSA-N Asp-Asn-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O UGKZHCBLMLSANF-CIUDSAMLSA-N 0.000 description 1
- UFAQGGZUXVLONR-AVGNSLFASA-N Asp-Gln-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)O)N)O UFAQGGZUXVLONR-AVGNSLFASA-N 0.000 description 1
- ZUNMTUPRQMWMHX-LSJOCFKGSA-N Asp-Val-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O ZUNMTUPRQMWMHX-LSJOCFKGSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 101100124986 Caenorhabditis elegans hsp-12.2 gene Proteins 0.000 description 1
- 101100071585 Caenorhabditis elegans hsp-16.2 gene Proteins 0.000 description 1
- 101100071600 Caenorhabditis elegans hsp-16.41 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000243988 Dirofilaria immitis Species 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- NJCALAAIGREHDR-WDCWCFNPSA-N Glu-Leu-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NJCALAAIGREHDR-WDCWCFNPSA-N 0.000 description 1
- ZYRXTRTUCAVNBQ-GVXVVHGQSA-N Glu-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZYRXTRTUCAVNBQ-GVXVVHGQSA-N 0.000 description 1
- STVHDEHTKFXBJQ-LAEOZQHASA-N Gly-Glu-Ile Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O STVHDEHTKFXBJQ-LAEOZQHASA-N 0.000 description 1
- FSPVILZGHUJOHS-QWRGUYRKSA-N Gly-His-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CNC=N1 FSPVILZGHUJOHS-QWRGUYRKSA-N 0.000 description 1
- 102100039165 Heat shock protein beta-1 Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- OMNVOTCFQQLEQU-CIUDSAMLSA-N His-Asn-Asp Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N OMNVOTCFQQLEQU-CIUDSAMLSA-N 0.000 description 1
- CHZKBLABUKSXDM-XIRDDKMYSA-N His-Asn-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC3=CN=CN3)N CHZKBLABUKSXDM-XIRDDKMYSA-N 0.000 description 1
- 101001036709 Homo sapiens Heat shock protein beta-1 Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- JGAMUXDWYSXYLM-SRVKXCTJSA-N Lys-Arg-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O JGAMUXDWYSXYLM-SRVKXCTJSA-N 0.000 description 1
- LPAJOCKCPRZEAG-MNXVOIDGSA-N Lys-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCCCN LPAJOCKCPRZEAG-MNXVOIDGSA-N 0.000 description 1
- ZJSZPXISKMDJKQ-JYJNAYRXSA-N Lys-Phe-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(O)=O)CC1=CC=CC=C1 ZJSZPXISKMDJKQ-JYJNAYRXSA-N 0.000 description 1
- RPWTZTBIFGENIA-VOAKCMCISA-N Lys-Thr-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O RPWTZTBIFGENIA-VOAKCMCISA-N 0.000 description 1
- RIPJMCFGQHGHNP-RHYQMDGZSA-N Lys-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)N)O RIPJMCFGQHGHNP-RHYQMDGZSA-N 0.000 description 1
- IKXQOBUBZSOWDY-AVGNSLFASA-N Lys-Val-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CCCCN)N IKXQOBUBZSOWDY-AVGNSLFASA-N 0.000 description 1
- GPAHWYRSHCKICP-GUBZILKMSA-N Met-Glu-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O GPAHWYRSHCKICP-GUBZILKMSA-N 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- 101710143583 Na(+)/H(+) exchange regulatory cofactor NHE-RF2 Proteins 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- MGLBSROLWAWCKN-FCLVOEFKSA-N Phe-Phe-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MGLBSROLWAWCKN-FCLVOEFKSA-N 0.000 description 1
- GURGCNUWVSDYTP-SRVKXCTJSA-N Pro-Leu-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O GURGCNUWVSDYTP-SRVKXCTJSA-N 0.000 description 1
- GMJDSFYVTAMIBF-FXQIFTODSA-N Pro-Ser-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O GMJDSFYVTAMIBF-FXQIFTODSA-N 0.000 description 1
- 240000005578 Rivina humilis Species 0.000 description 1
- LVVBAKCGXXUHFO-ZLUOBGJFSA-N Ser-Ala-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O LVVBAKCGXXUHFO-ZLUOBGJFSA-N 0.000 description 1
- OYEDZGNMSBZCIM-XGEHTFHBSA-N Ser-Arg-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OYEDZGNMSBZCIM-XGEHTFHBSA-N 0.000 description 1
- FIDMVVBUOCMMJG-CIUDSAMLSA-N Ser-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO FIDMVVBUOCMMJG-CIUDSAMLSA-N 0.000 description 1
- 101710150310 Stress-induced protein 1 Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- WFUAUEQXPVNAEF-ZJDVBMNYSA-N Thr-Arg-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CCCN=C(N)N WFUAUEQXPVNAEF-ZJDVBMNYSA-N 0.000 description 1
- YLXAMFZYJTZXFH-OLHMAJIHSA-N Thr-Asn-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)O YLXAMFZYJTZXFH-OLHMAJIHSA-N 0.000 description 1
- TZJSEJOXAIWOST-RHYQMDGZSA-N Thr-Lys-Arg Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CCCN=C(N)N TZJSEJOXAIWOST-RHYQMDGZSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- DEZKIRSBKKXUEV-NYVOZVTQSA-N Trp-Asp-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)O)N DEZKIRSBKKXUEV-NYVOZVTQSA-N 0.000 description 1
- FMXFHNSFABRVFZ-BZSNNMDCSA-N Tyr-Lys-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O FMXFHNSFABRVFZ-BZSNNMDCSA-N 0.000 description 1
- OVLIFGQSBSNGHY-KKHAAJSZSA-N Val-Asp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N)O OVLIFGQSBSNGHY-KKHAAJSZSA-N 0.000 description 1
- FPCIBLUVDNXPJO-XPUUQOCRSA-N Val-Cys-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CS)C(=O)NCC(O)=O FPCIBLUVDNXPJO-XPUUQOCRSA-N 0.000 description 1
- URIRWLJVWHYLET-ONGXEEELSA-N Val-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)C(C)C URIRWLJVWHYLET-ONGXEEELSA-N 0.000 description 1
- CPGJELLYDQEDRK-NAKRPEOUSA-N Val-Ile-Ala Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](C)C(O)=O CPGJELLYDQEDRK-NAKRPEOUSA-N 0.000 description 1
- KNYHAWKHFQRYOX-PYJNHQTQSA-N Val-Ile-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](C(C)C)N KNYHAWKHFQRYOX-PYJNHQTQSA-N 0.000 description 1
- 241000244002 Wuchereria Species 0.000 description 1
- 102100028458 Zinc finger E-box-binding homeobox 2 Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003115 checkerboard titration Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229940099686 dirofilaria immitis Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 101150009602 mesh gene Proteins 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910001453 nickel ion Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 108010084932 tryptophyl-proline Proteins 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56905—Protozoa
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to field of biotechnology, disclose a kind of ELISA kit for diagnosing heartworm disease.Kit of the present invention includes the solid phase carrier for being coated with heart worm small heat shock protein.Related application the present invention provides heart worm small heat shock protein as heartworm disease diagnostic antigen, related experiment is as the result is shown, heart worm small heat shock protein can be identified by the dog serum of natural infection heartworm disease, the rabbit-anti IgG of heart worm small heat shock protein preparation can identify heart worm small heat shock protein, have good immunogenicity and reactionogenicity;High sensibility and specificity is shown in indirect ELISA method simultaneously, various results prove that heart worm small heat shock protein can be used as the diagnostic antigen of heartworm disease, and are applied in coherent detection kit.
Description
Technical field
The present invention relates to field of biotechnology, in particular to a kind of ELISA kit for diagnosing heartworm disease.
Background technique
Heartworm disease is a kind of infecting both domestic animals and human parasitic disease propagated by mosquito matchmaker.Heart worm (Dirofilaria
Immitis) main parasitic can cause host in the pulmonary artery and right ventricle of dog, cat, the heart worm adult for colonizing in pulmonary artery
Vascular lesion and the reaction such as pulmonary hypertension.Since global warming increases the activity of mosquito matchmaker, in recent years in relation to people
The Case report for infecting heartworm disease is in rising trend.
The routine diagnostic method of heartworm disease mainly has Pathogen test, Serologic detection and molecular Biological Detection.Mesh
Before, Serologic detection is most common detection method, is divided into antigen detection and antibody test.The false negative result of antigen detection is normal
See that mild infection, female adult are not yet mature, only infect situations such as male worm;Antibody test is compared with the advantage that antigen detects, no matter
Female adult or male worm can detected.For host infection heart worm after 2 months, larva stimulates immune response caused by body
It can be detected, antibody test can detect heart worm than antigen detection earlier, the morning suitable for heartworm disease
Phase detection.The new diagnostic method of the effective heartworm disease of exploration discovery has important show for the efficient diagnosis of heartworm disease
Sincere justice.
Summary of the invention
In view of this, the purpose of the present invention is to provide a kind of ELISA kits for diagnosing heartworm disease, so that described
Kit has higher specificity and sensibility when detecting.
For achieving the above object, the invention provides the following technical scheme:
A kind of ELISA kit diagnosing heartworm disease, including it is coated with heart worm small heat shock protein (Di-
SHSP12.6 solid phase carrier).In the specific embodiment of the invention, the solid phase carrier may be selected to be 96 well culture plates or with
Its similar solid phase carrier, the heart worm small heat shock protein peridium concentration are 100 holes μ l/, and coating buffer coating can be used
In on carrier, coating buffer is by 0.39g Na2CO3, 35mM NaHCO3, 0.2M NaCl, tune PH to 9.6 are obtained.
After kit core component has been determined, the ELISA kit further include ELIAS secondary antibody, cleaning solution, developing solution,
One or more of confining liquid, dilution, terminate liquid.
Wherein, the ELIAS secondary antibody is preferably the rabbit-anti dog IgG of HRP label, described in the specific embodiment of the invention
ELIAS secondary antibody uses the product purchased from Wuhan Boster Biological Technology Co., Ltd., and ELIAS secondary antibody dilution ratio is 1:2000;
The cleaning solution is preferably PBS-T cleaning solution, in the specific embodiment of the invention, the PBS-T cleaning solution group
Become: 8gNaCl, 0.2gKCl, 1.42gNa2HPO4, 0.27gKH2PO4, it is dissolved in 800mL deionized water, is added
0.5mLTween20 is dissolved to 1L;The developing solution is preferably TMB developing solution;
The confining liquid is preferably skim milk, and in the specific embodiment of the invention, the skimmed milk concn is
5%.
The terminate liquid is preferably sulfuric acid solution, and concentration is preferably 2mol/L;Preparation method is to delay in 178mL deionized water
Slow 98% concentrated sulfuric acid that 21.7mL is added dropwise, is cooled to room temperature, 4 DEG C of preservations;
The dilution is preferably PBS;Preparation method is 8gNaCl, 0.2gKCl, 1.42gNa2HPO4, 0.27gKH2PO4,
It is dissolved in 800mL deionized water, is dissolved to 1L, after sterilizing, room temperature preservation.
Herein, heart worm small heat shock protein can be non-natural, e.g. synthesizing or by manually carrying
(being frequently referred to recombinant protein rDi-sHSP12.6 in the industry) that body surface reaches.Term " non-natural " refers to that target substance is not nature
Naturally occurring, the non-natural substances and naturally occurring material structure and/or composition having the same are not precluded in this.
In nematode, it has now been found that 14 kinds of small heat shock proteins (small heat shockprotein,
SHSP), be segmented into 6 groups: sHSP12s according to the difference of molecular mass (including HSP12.1, HSP12.2, HSP12.3 and
HSP12.6), sHSP16s (HSP16.1, HSP16.2, HSP16.41, HSP16.48 and newfound F08H9.3,
F08H9.4), HSP25, HSP43, HSP17.5 and stress-inducing albumen -1 (stress-induced protein-1, SIP-1),
Research confirms that it can not only maintain protein conformation necessary to cell under stressed condition, protection cell activities with
Cells survival is maintained, and in protein folding, transdermal delivery, transhipment, immunity of organism, Apoptosis, cytoskeleton and bony nodule
It plays an important role in the basic functions such as frame stabilization.Currently, heart worm small heat shock protein (Di-sHSP12.6) is in dog
There is not been reported for correlative study in dirofilariasis.
The present invention obtains recombination heart worm small heat shock protein (rDi-sHSP12.6, and Di- by prokaryotic expression
SHSP12.6 has identical amino acid sequence, as shown in SEQ ID NO:1), carry out immunoblotting to it, ELISA with
And the foundation of method of early diagnosis.Immunoblot results show that the rabbit-anti IgG of recombinant protein rDi-sHSP12.6 preparation can be identified
Recombinant protein rDi-sHSP12.6, recombinant protein rDi-sHSP12.6 can identify by the dog serum of natural infection heartworm disease,
It cannot be identified by healthy dog serum, illustrate that heart worm small heat shock protein has good immunogenicity and reactionogenicity.
Result of indirect ELISA is shown, with 24 parts of heart worm positive serums of rDi-sHSP12.6 Protein Detection and 24 portions of dogs
Filaria negative serum is disliked, the results show that 22 parts of positive serum OD450 > critical values, 2 parts of positive serums and 24 parts of negative serums
OD450 < critical value (0.699), then the sensibility for assessing this method is 91.6% (22/24);Meanwhile not with dog particulate spine ball silk ribbon
Worm positive serum, dog cysticercus tenuicollis positive serum and dog hookworm positive serum (totally 18 parts) generation cross reaction, the 18 of detection
Slight cross reactions occur for only 2 parts in part Toxocara canis positive serum, then the specificity for assessing this method is 91.6%
(34/36);In conclusion rDi-sHSP12.6 sensibility and specificity with higher, and cross reacting rate is low, has preferable
Diagnosis effect, be suitable as the diagnostic antigen of heartworm disease and prepare relevant detection kit as diagnostic antigen.
From the above technical scheme, the present invention provides heart worm small heat shock proteins diagnoses as heartworm disease
The related application of antigen, related experiment is the results show that heart worm small heat shock protein can be by natural infection heartworm disease
The rabbit-anti IgG of dog serum identification, the preparation of heart worm small heat shock protein can identify heart worm small heat shock protein, have good
Good immunogenicity and reactionogenicity;High sensibility and specificity, various results are shown in indirect ELISA method simultaneously
It proves that heart worm small heat shock protein can be used as the diagnostic antigen of heartworm disease, and is applied to coherent detection kit
In.
Detailed description of the invention
Fig. 1 show the PCR amplification of Di-sHSP12.6 gene;Wherein, M is DNA molecular quality standard (DL2000);1-
4:Di-sHSP12.6PCR product;
Fig. 2 show the double digestion identification of recombinant plasmid pET32a (+)-sHSP12.6;Wherein, M:DNA molecular mass mark
Quasi- (DL2000);The double enzyme digestion product of 1-4:pET32a (+)-sHSP12.6;
Fig. 3 show the expression of recombination Di-sHSP12.6 albumen;Wherein, M: protein standard;1:IPTG is lured
That leads does not contain the Escherichia coli of pET32a (+)-sHSP12.6;The large intestine containing pET32a (+)-sHSP12.6 of 2-4:IPTG induction
Bacillus;
Fig. 4 show the soluble analysis of rDi-sHSP12.6;Wherein, M: protein standard;1:8M urea
Dissolution;The dissolution of 2:4M urea;The dissolution of 3:2M urea;4: supernatant;
Fig. 5 show the expression, purifying and immunoblotting assay of rDi-sHSP12.6;Wherein, what 1:IPTG was induced does not contain
There are the Escherichia coli of recombination pET32a (+)-sHSP12.6;2:IPTG induction contains the big of recombination pET32a (+)-sHSP12.6
Enterobacteria;3: the IgG of the rabbit-anti rDi-sHSP12.6 after ni-sepharose purification;4: the rDi-sHSP12.6 after ni-sepharose purification;5:
The dog positive serum specific recognition rDi-sHSP12.6 of natural infection heart worm;6: the rabbit-anti rDi- after ni-sepharose purification
The IgG of sHSP12.6 identifies rDi-sHSP12.6;7: healthy negative dog serum identifies rDi-sHSP12.6;
Fig. 6 show the indirect immunofluorescence positioning of female and male heart worm cross section Di-sHSP12.6 albumen;Its
In, I: intestines;UT: uterus;TE: testis;MU: muscle;HY: funiculus lateralis;PS: pseudocoele;Scale bar: 200 μm;A, B: female adult;C, D:
Male worm;Note: green fluorescence region is that albumen is distributed Position Approximate;
Fig. 7 show the indirect ELISA (specificity) of recombinant protein rDi-sHSP12.6;
Fig. 8 show the indirect ELISA (sensibility) of recombinant protein rDi-sHSP12.6.
Specific embodiment
The invention discloses a kind of ELISA kit for diagnosing heartworm disease, those skilled in the art can use for reference this
Literary content, is suitably modified realization of process parameters.In particular, it should be pointed out that all similar substitutions and modifications are to art technology
It is it will be apparent that they are considered as being included in the present invention for personnel.Kit of the present invention has passed through embodiment
It is described, related personnel can obviously not depart from the content of present invention, carried out in spirit and scope to kit described herein
Change or appropriate changes and combinations, carry out implementation and application the technology of the present invention.
The present invention is by extracting heart worm adult polypide total serum IgE, and reverse transcription is cDNA, and dog is expanded from cDNA and dislikes silk
Worm small heat shock protein (Di-sHSP12.6) coded sequence.After T is cloned, amplified production is imported in a manner of digestion connection
In expression vector, the rDi-sHSP12.6 that prokaryotic expression obtains recombination is carried out with Escherichia coli.
In the experiment of specific embodiment party, all experimental animals are in strict accordance with " People's Republic of China's Animal Protection Law "
(draft of publication on September 18th, 2009) is handled.All programs are in strict accordance with " the animal welfare committee, Sichuan Agricultural University
Experimental animal care guidelines " (China, Yaan;Approval number: 2013-028) implement.All methods are according to correlation criterion and regulation
It carries out, including any correlative detail.
Dog of the heart worm polypide from Sichuan Province's natural infection and dissect, polypide are clear using PBS from after the separation of dog heart
It washes, is heart worm through Morphological Identification referring to related documents and materials.Heartworm disease positive serum picks up from Sichuan Province's natural sense
Contaminate the positive dog of heart worm.The dog that serum for cross reaction picks up from the dissect after excrement inspection or natural death is (dead
It is preceding to have acquired blood);Negative serum picks up from spring through inside and outside expelling parasite treated 3 monthly age beasle dogs (testing dedicated dog).
Experimental animal is 2 healthy new zealand rabbits, and female, at or so 3 monthly ages, 1.5~2.0kg reaches large biology purchased from Chengdu
Co., Ltd.
Bacterial strain and plasmid: bacillus coli DH 5 alpha, e. coli bl21 (DE3) are purchased from Tiangeng company;TaKaRa pMD19-T
Vector is purchased from Dalian treasured bioengineering Co., Ltd;Prokaryotic expression carrier pET32a (+) is purchased from Invitrogen.
Just a kind of ELISA kit for diagnosing heartworm disease provided by the present invention is described further below.
Embodiment 1: gene magnification
1, the extraction of heart worm total serum IgE
Be prepared in advance -80 DEG C of mortars being pre-chilled, and is removed from liquid nitrogen heart worm adult polypide (about 20mg), shreds
Afterwards, a little liquid nitrogen is added and is fully ground, is indicated then according to Tiangeng animal tissue RNA extracts kit, extracts heart worm
Total serum IgE, -80 DEG C of preservations.
2, first chain of cDNA is synthesized
Using the heart worm total serum IgE of extraction as template, OligodT (18) is primer, is tried according to the reverse transcription of Thermo company
The instruction of agent box, synthesizes first chain of cDNA.
3, the design and synthesis of primer
Referring to Wuchereria malayi sHSP12.6 nucleotide sequence (gb:XM_001900555.1) in NCBI, utilize
Primerpremier5.0 design primer, underscore part are restriction enzyme site (BamH I and Xho I):
Di-sHSP12.6 upstream primer (F): CGGATCCATGGAAGAAAAGGTAGTGGA
Di-sHSP12.6 downstream primer (R): CGAGCTCTCATGCTTTCTTTTTGGC
4, amplification program and system
PCR amplification is carried out by substrate template of heart worm cDNA.Amplification program is shown in Table 1, and amplification system is shown in Table 2:
Table 1
Table 2
5, product recycles
After above-mentioned product is carried out nucleic acid gel electrophoresis, it is whether correct that stripe size is compared under gel imaging system.So
It cuts purpose band in the UV lamp afterwards, and DNA is carried out to purpose band according to Tiangeng biotechnology company's plastic recovery kit
Recycling, -20 DEG C of preservations.
6, the amplification of Di-sHSP12.6 gene and basic physical and chemical attribute
Go out the band (Fig. 1,1-4 swimming lane) of 340bp or so using heart worm cDNA as template amplification, raw work biology has
Limit company sequencing result shows that the sequence homology in the sequence and NCBI reaches 100%.
The Di-sHSP12.6 mrna length that the present invention expands encodes 113 amino through amino acid sequence analysis for 342bp
Acid (last 3 bases be terminator codon, do not encode amino acid), molecular mass 13052.71, thus it is speculated that its molecular formula is
C575H910N162O179S3, ProtParam prediction Di-sHSP12.6 albumen mainly contain Val, Thr, Lys and Asp.Signal peptide point
Di-sHSP12.6 no signal peptide, transmembrane region predictive display Di-sHSP12.6 are located at extracellular region as the result is shown for analysis.
Embodiment 2: clone and identification
1, it connects
The purpose band DNA fragmentation of recycling is connected with pMD19-T carrier, 16 DEG C (are no more than 16h) overnight, connector
System is shown in Table 3:
Table 3
2, it converts
It takes out the 8 μ L of product connected to be placed in the EP pipe of 1mL, 30 μ LE.coliDH5 α competent cells is added, use is micro-
Amount sample injector mixes gently, ice bath 30min, 42 DEG C of water-bath 90s, then ice bath 5min.600 μ LLB Liquid Cultures are added into EP pipe
Base takes 100 μ L bacterium solutions to be uniformly inoculated in the solid of benzyl containing ammonia (AMP) resistance after cultivating 1.5h in 37 DEG C, 180r/min environment
On culture medium, 12h is cultivated in 37 DEG C of constant incubators.
3, sequencing identification
Select that form is normal, the single bacterium colony of dispersion is inoculated in 1mLLB fluid nutrient medium (containing 1 μ LAMP), and 37 DEG C
6h is cultivated in 180r/min environment, the band that whether can amplify target fragment size identified, purpose will be amplified by bacterium solution PCR
The bacterium solution of segment takes 400 μ L that raw work biology Co., Ltd is sent to be sequenced.Bacterium solution PCR reaction system is shown in Table 4:
Table 4
Embodiment 3: construction of expression vector
1, plasmid is extracted
Correct bacterium solution is sequenced in embodiment 2 to expand culture, is extracted according to the small extraction reagent kit specification of Tiangeng plasmid
The plasmid of Di-sHSP12.6, and finally draw 5 μ L mixing, 5 μ Lloadingbuffer and carry out accounting gel electrophoresis, detect plasmid
Purity.
2, the digestion recycling of target gene plasmid and expression vector plasmid
The plasmid of expression vector pET32a (+) is obtained by target gene plasmid and according to the method for 2.3.1, use is identical
The fast enzyme cutting of Takara carries out digestion, obtains identical cohesive terminus,cohesive termini.With (BamH I and Sac I) fast enzyme cutting to Di-sHSP12.6 and
PET32a (+) expression vector plasmid carries out digestion.Target gene plasmid after digestion and expression are carried according to the method in embodiment 1
The DNA fragmentation of constitution grain carries out glue recycling.
3, target gene connects expression vector
The DNA fragmentation recycled in 2 is taken respectively, is attached with T4 ligase, building pET32a (+)-recombinant protein expression
Vector plasmid.After brief centrifugation, 22 DEG C of connection 2h in PCR instrument.It is converted according to method in embodiment 2.
4, the double digestion identification of recombinant plasmid
Recombinant plasmid is obtained according to method in 1, respectively with corresponding fast enzyme cutting to recombinant plasmid double digestion, and carries out nucleic acid
Gel electrophoresis determines that target gene has been coupled on expression vector.400 μ L are taken to send raw work biology limited public affairs determining bacterium solution
Department's sequencing.
Through nucleic acid gel electroresis appraisal, recombinant plasmid energy digestion goes out the segment with target gene size, with expected results phase
With (Fig. 2).Recombination Di-sHSP12.6 plasmid is transferred in BL21 Escherichia coli, after the plate screening via AMP resistance, is chosen
The single bacterium colony of form rule is taken to carry out bacterium colony PCR identification, positive bacteria send raw work biology Co., Ltd to be sequenced, sequencing sequence and mesh
Gene order it is identical, show construction of expression vector success.
Embodiment 4: the prokaryotic expression of albumen
(1) correct bacterium solution will be sequenced in embodiment 2 to expand culture, and obtains recombination according to method in embodiment 3
Plasmid.
(2) it takes 10 μ L plasmids to be placed in the EP pipe of 1mL, 50 μ LE.coliBL21 competent cells is added, use micro sample-adding
Device mixes gently, ice bath 30min, 42 DEG C of water-bath 90s, then ice bath 5min.600 μ LLB liquid mediums are added into EP pipe, in
37 DEG C, after cultivating 1.5h in 180r/min environment, 150 μ L bacterium solutions is taken uniformly to be inoculated in the solid culture of benzyl containing ammonia (AMP) resistance
On base, 12h is cultivated in 37 DEG C of constant incubators.
(3) PCR identification is carried out according to method in embodiment 2, PCR is accredited as positive bacterium solution and carries out 5mL expansion culture,
37 DEG C, 180r/min is cultivated to value=0.6 OD, and inducer IPTG (1mmol/L) is added and induces 6h, another bottle is not added IPTG and does sky
White control.
(4) bacterium solution after taking 1mL to induce 4 DEG C, 12000r/min, is centrifuged 1min, collects bacterial sediment, 40 μ are added
LddH2O and 10 μ L5 × SDS loading Buffer is mixed.
(5) after heating 10min in boiling water, 4 DEG C, 12000r/min, it is centrifuged 1min, appropriate supernatant is taken to carry out SDS-PAGE.
(6) PAGE glue is removed, is put into the container equipped with coomassie brilliant blue staining agent, dyeing 30min or so, in boiling water
Decolourize 10min, observes result under gel imaging system.
SDS-PAGE shows to obtain about 30KDa, and (Di-sHSP12.6 size is about 12KDa, and His tag size is about
18KDa) (Fig. 3).
Embodiment 5: the soluble analysis of recombinant protein
Will the bacterium of successful expression be inoculated in 1LLB fluid nutrient medium (g/mL of μ containing AMP100), 37 DEG C, 180r/min
3h is cultivated, to OD=0.6,10mLIPTG is added and induces 6h.By 4 DEG C of all bacterium solutions, 12000r/min is centrifuged 10min, abandons supernatant
Retain remaining thallus and suspension is then put into mixture of ice and water with the Tris-HCl lytic cell wall of 10mL (50mmol/L)
In, sonicated cells.4 DEG C, 12000r/min, it is centrifuged 10min, takes supernatant according to method sample preparation in embodiment 4.Sediment point
Not Yong the dissolution of gradient urea, then supernatant is collected by centrifugation respectively according to method sample preparation in embodiment 4.Gained sample is subjected to SDS-
After PAGE, it is imaged in gel imaging system.RDi-sHSP12.6 albumen is expressed at supernatant (Fig. 4) as the result is shown.
Embodiment 6: the purifying of recombinant protein
Will the bacterium of successful expression be inoculated in 1LLB fluid nutrient medium (g/mL of μ containing AMP100), 37 DEG C, 180r/min
3h is cultivated, to OD=0.6,10mLIPTG is added and induces 6h, obtains recombinant protein bacterium solution.
(1) by 4 DEG C, 12000r/min of all bacterium solutions, it is centrifuged 10min, abandons supernatant, retains thallus.
(2) suspension, is then put into mixture of ice and water by the Tris-HCl lytic cell wall for using 10mL (50mmol/L),
Sonicated cells.
(3) 4 DEG C, 12000r/min, it is centrifuged 10min, collects supernatant.
(4) precipitating uses 2mol/L, 4mol/L, 6mol/L respectively, and the urea liquid of 8mol/L washs, then 4 DEG C, 12000r/
Min is centrifuged 10min, collects supernatant.
(5) it with the above-mentioned gained supernatant of 0.45 μm of membrane filtration, is placed in spare in mixture of ice and water.
(6) with 0.22 μm of membrane filtration BandingBuffer and ElutionBuffer, it is placed in ice together with 20% alcohol
It is spare in aqueous mixtures, bubble removing is removed using preceding ultrasound 1-2min.
(7) nickel ion affinity chromatograph column is taken out, is connected on protein purification instrument, with BandingBuffer balance 5-10
Bed volume.
(8) albumen is injected, balances 5-10 bed volume to BandingBuffer, is started respectively with 13%, 25%, 50%,
75% and 100% ElutionBuffer (imidazoles containing 400mM) is eluted, eluting peak to appear, starts to collect albumen sample
Product.
(9) ultrafiltration that recombinant protein is carried out according to super filter tube application method, is during which added after 0.22 μm of membrane filtration and goes out
The PBS of bacterium carries out the displacement of imidazoles and other substances.
(10) albumen after ultrafiltration measures protein concentration using ultramicron ultraviolet specrophotometer, 1-2 drop glycerol is added
- 80 DEG C of preservations afterwards, to guarantee the stabilization of albumen.
The purification effect of rDi-sHSP12.6 (Fig. 5, swimming lane 4) albumen is good as the result is shown.
Embodiment 7: the analysis of recombinant protein immunogenicity and reactionogenicity
2.7.1 the preparation of rabbit-anti recombinant protein IgG
The incomplete Freund's adjuvant or Freund's complete adjuvant of equivalent will be added in albumen after purification, so that albumen is dense eventually
Degree is 0.2mg/mL, and ultrasound is to Water-In-Oil state emulsion formulation (instill water in 1min indiffusion) in Ultrasonic Cell Disruptor.Points 4 times right
New zealand rabbit carries out subcutaneous injection and is immunized, and specific immune programme is shown in Table 5:
Table 5
4th time immune 7 days latter, from rabbit ear edge vein exploitating blood, and separates -20 DEG C of serum preservations.
2, the thick of IgG mentions
(1) it takes 10mL serum to add physiological saline 10mL, then (NH is added dropwise4)2SO4Saturated solution 5mL is (until generate wadding
Until shape precipitates), make 20% (NH4)2SO4Solution, it is stirring while adding, stand 30min
It (2) 4 DEG C, 3000r/min, is centrifuged 20min, abandons precipitating (except defibrinating).
(3) (NH4) 2SO4 saturated solution 15mL or so is added into supernatant, makes 50% (NH4)2SO4Solution, it is quiet
Set 30min.
(4) 4 DEG C, 3000r/min, it is centrifuged 20min, abandons supernatant.
(5) precipitating can go up column purification with A2BangdingBuffer after completely dissolution.
3, the purifying of IgG
(1) purification column is installed on instrument by correct step, with preceding 20% alcohol rinse instrument pipe, until balance.
(2) pillar is balanced with A2BangdingBuffer, until ion line balance.
(3) IgG slightly mentioned is injected into instrument, is continued A2BangdingBuffer and is balanced pillar to ion line balance.
(4) it is then eluted with BBuffer, after there is eluting peak, controls as low flow velocity, collect IgG sample after purification, stand
It is neutralized with Tris, PH=8.0 or so.
(5) the step of repeating sample-adding purifying, repeating (2)-(4).
(6) after having purified, it is full of instrumentation tube with 20% alcohol, until ion line balance.
(7) a small amount of IgG after purification is taken to verify according to method sample preparation in embodiment 4.
Rabbit-anti r-Di-sHSP12.6 (Fig. 5, swimming lane 3) protein I gG is prepared according to the method described above, and passes through the affine layer of nickel column
Analysis purifies rabbit-anti recombinant protein IgG, works well, and occurs the heavy chain of 50KDa or so and 25KDa or so respectively
Light chain.
4, the immunoblotting of Di-sHSP12.6 albumen
(1) recombinant protein is subjected to SDS-PAGE.
(2) gel redundance is cut, 24 layers of filter paper (2) and nitrocellulose filter (NC film) is cut respectively, sets jointly
It is balanced 3 times in transferring film buffer, each 5min.
(3) gel by balance after good, filter paper and NC film, according to negative battery plate, filter paper, gel, NC film, the sequence of filter paper
It stacks, and removes intermediate extra bubble with glass rod.
(4) anode battery plate is covered, electric current is configured according to 1mA/cm2, and corotation moves 30min.
(5) after transferring film, gel coomassie brilliant blue staining is taken out, the effect of transferring film is observed in gel imaging system
Rate.
(6) NC film is put into container, carries out washing 3 times, each 5min with TBST.
(7) skimmed milk power that 5% is added into container closes 2h, and primary antibody (heart worm positive serum or preparation is added
Rabbit-anti IgG), after being diluted according to 1:100,4 DEG C, overnight.
(8) primary antibody is abandoned, is washed 3 times, each 5min with TBST, secondary antibody (HRP- marks rabbit-anti dog IgG) is added, according to
After PBS1:2000 dilution, it is incubated for 2h at room temperature.
(9) secondary antibody is abandoned, is washed 3 times, each 5min with TBST, NC film is taken out and is placed in clean container, be added dropwise on NC film
Diaminobenzidine (DAB) developing solution of fresh configuration.
(10) it after there is band, is terminated react with distilled water immediately, taken pictures in gel imaging system.
It is analyzed according to immunogenicity and reactionogenicity of the method among the above to rDi-sHSP12.6 albumen.Diagnosis of Sghistosomiasis
R-Di-sHSP12.6 albumen has good immunogenicity and reactionogenicity to mark as the result is shown.The rabbit-anti IgG of recombinant protein preparation
It can identify that recombinant protein (Fig. 5, swimming lane 6, shown in white arrow), recombinant protein can be by the dog blood of natural infection heartworm disease
Clear identification, cannot be identified by healthy dog serum, illustrate the albumen have good reactionogenicity and immunogenicity (Fig. 5, swimming lane 5,
Shown in white arrow).
5, indirect immunofluorescence positions
(1) it is sliced: by the fixed heart worm female insect paraffin embedding of 4% paraformaldehyde and being sliced (thickness 4mm).
(2) it bakes piece: slice is placed in 2h in 60 DEG C of insulating boxs.
(3) by baked slice in the following order carry out dewaxing and aquation: dimethylbenzene I (7min), dimethylbenzene II (7min),
100% alcohol I (3min), 100% alcohol II (3min), 95% alcohol (3min), 85% alcohol (3min), 75% alcohol
(3min), distilled water (8min).
(4) slice after the completion of dewaxing and aquation is put into antigen hot repair in sodium citrate buffer solution to answer, 95 DEG C or more add
Hot 15min.Slice is rinsed 3 times, 5min/ times with PBS after cooling.
(5) organizationally with 3%H2O2 drop, it 37 DEG C, 25min, is washed 3 times, 5min/ times with PBS.
(6) 5%BSA confining liquid, room temperature, 45min is added dropwise to tissue.
(7) surplus liquid is abandoned, rabbit-anti recombinant protein IgG (1:100 dilution) is added, 4 DEG C of overnight incubations in wet box;PBS is washed
It washs 3 times, 4min/ times.
(8) goat anti-rabbit igg (1:100 dilution) marked with the 0.1% diluted FITC of Azo-Blue is added, 37 DEG C are protected from light
It is incubated for 1h.
(9) PBS is washed 3 times, 4min/ times.
(10) mounting is carried out with qs glycerin buffer, slice is placed in fluorescence microscopy under the microscope and be imaged.
Indirect IF staining detects Di-sHSP12.6 in the distribution of female and male heart worm adult cross section,
SHSP12.6 is distributed mainly in the epidermis and intestines of female heart worm as the result is shown, there is a small amount of distribution in muscle;In male dogs
It dislikes in filaria body and is distributed mainly on epidermis, and can be secreted into enteron aisle, be also only distributed on a small quantity in muscle (Fig. 6, A, B, C, D,
Wherein A, C are the positive, and B, D are feminine gender).
The foundation of embodiment 8:rDi-sHSP12.6 albumen indirect ELISA method
1, operating method
(1) 96 hole elisa Plates are taken, dilute recombinant protein (antigen) with coating buffer, 0 hole μ L/ of protein 10 that addition has diluted, 4
DEG C, coating is overnight.
(2) protein liquid is abandoned, wash 3 times with PBST, 5min/ time, concussion is cleaned in Yu Weiliang concussion instrument, (it fills it up with as far as possible, but
Hole cannot be gone here and there).
(3) 5% skimmed milk power is added, 250 holes μ L/, are incubated for 1.5h by 37 DEG C.
(4) PBST is washed 3 times, 5min/ times.
(5) serum diluted with PBS is added, 100 holes μ L/, are incubated for 1h by 37 DEG C.
(6) PBST is washed 3 times, 5min/ times.
(7) the rabbit-anti dog IgG for diluting HRP label in proportion with PBS is added, 100 holes μ L/, are incubated for 1h by 37 DEG C.
(8) PBST is washed 4 times, 5min/ times.
(9) soluble one pack system substrate TMB developing solution, 100 holes μ L/ are added into 96 hole elisa Plates, room temperature is protected from light incubation
20min。
(10) H of 2mol/L is added2SO4, 100 holes μ L/ terminate reaction.
(11) 96 orifice plates are placed in microplate reader, measure its OD value (λ=450nm).
A kind of kit can be formed according to the indirect ELISA reagent of the present embodiment.
2, condition optimizing
(1) optimal antigen coat concentration and serum-concentration are determined: referring to Checkerboard titration method, it is dense that 6 antigen coats being set
Degree is such as: (20.20 μ g, 10.10 μ g, 5.05 μ g, 2.53 μ g, 1.26 μ g and the 0.63 every hole μ g/) and 4 serum dilutions (1:20,
1:40,1:80 and 1:160), after completing test according to 2.8.1 method, in measuring reading in microplate reader, P/N value is calculated, is determined
Optimal antigen coat concentration and serum-concentration.With positive serum OD450 close to the maximum condition of 1, P/N as best.
(2) it determines optimal confining liquid: according to optimal antigen coat concentration and serum-concentration, using 5% degreasing respectively
Milk powder and 5% BSA as confining liquid, complete to calculate P/N value in measuring reading in microplate reader, determine optimal after test
Confining liquid.With positive serum OD450 close to the maximum condition of 1, P/N as best.
(3) optimal primary antibody incubation time is determined: according to optimal antigen coat concentration, serum-concentration and confining liquid, if
4 unused incubation times (0.5h, 1h, 1.5h and 2h) are stood, is read after completing test in measurement in microplate reader, calculates P/N
Value, determines optimal primary antibody incubation time.With positive serum OD450 close to the maximum condition of 1, P/N as best.
(4) determine that optimal secondary antibody is incubated for concentration: when being incubated for according to optimal antigen coat concentration, serum-concentration and primary antibody
Between, set up 5 different secondary antibody dilutions (1:1000,1:2000,1:3000,1:4000 and 1:5000), complete after test in
Reading is measured in microplate reader, calculates P/N value, determines that optimal secondary antibody is incubated for concentration.With positive serum OD450 close to 1, P/N
Maximum condition is as best.
(5) determine optimal developing time: according to above optimum condition, set up 5 different developing times (10min,
15min, 20min, 25min, 30min), it is read after completing test in measurement in microplate reader, calculates P/N value, determine optimal
Developing time.With positive serum OD450 close to the maximum condition of 1, P/N as best.
3, the determination of critical value
It is tested according to the experimental condition optimized in 2.8.2, critical value is determined using cutoff value method.Measure 24 portions of dogs
Dirofilariasis negative serum OD450 calculates the average and standard deviation of all serum OD450.Cutoff value=average value+3
Times standard deviation, is arranged 3 repetitions.
4, the determination of specificity and sensibility
It is tested according to the experimental condition optimized in 2, respectively to the collected dog Echinococcus granulosus in this laboratory sun
Property serum (8 parts), dog cysticercus tenuicollis positive serum (2 parts), dog hookworm positive serum (8 parts) and Toxocara canis serum (18
Part) respectively carry out cross reactivity measurement.According to the critical value determined in 3, corresponding specificity and sensibility, meter are calculated
It is as follows to calculate formula: specificity=true negative serum number/(true negative serum number+false positive serum number) × 100%, sensibility=true
Positive serum number/(true positives serum number+false negative serum number) × 100%, 3 repetitions of every group of setting.
According to the indirect ELISA method of optimization, with rDi-sHSP12.6 Protein Detection dog Echinococcus granulosus positive serum
(8 parts), dog cysticercus tenuicollis positive serum (2 parts), dog hookworm positive serum (8 parts) and Toxocara canis serum (18 parts), knot
Fruit shows, does not hand over dog Echinococcus granulosus positive serum, dog cysticercus tenuicollis positive serum and dog hookworm positive serum
Fork reacts, and slight cross reactions (Fig. 7) occurs for only 2 parts in 18 parts of Toxocara canis positive serums of detection, specificity is
94.4% (34/36).
5, the repeatability of detection test
(1) Repeatability checking in criticizing: being coated with the recombinant protein of same concentrations in same 96 hole elisa Plates, detects 6 parts
Determining heartworm disease positive serum, every part of serum repeats 3 holes, according to the ELISA method optimized, carries out batch interior repetition
Test calculates the coefficient of variation, repeatability in inspection lot.
(2) Repeatability checking between criticizing: being coated with the recombinant protein of same concentrations in 3 96 hole elisa Plates respectively, detects 6 parts
Determining heartworm disease positive serum, every part of serum repeats 3 holes, according to the ELISA method optimized, repeat between criticizing
Test calculates the coefficient of variation, repeatability between inspection lot.
Interassay coefficient of variation is (5.63%-8.15%), and variation within batch coefficient is (0.96%-3.89%), batch variation
For coefficient less than 10%, variation within batch coefficient shows that the test has good repeatability less than 5%.
6, clinical detection
It is negative to 24 parts of heartworm disease positive serums and 24 heartworm diseases respectively with established indirect ELISA method
Serum is detected, and according to critical value, specificity and sensibility judge the reliability of ELISA method.
According to the indirect ELISA method of optimization, with 24 parts of heart worm positive serums of rDi-sHSP12.6 Protein Detection and
24 parts of heart worm negative serums, the results show that 22 parts of positive serum OD450 > critical values, 2 parts of positive serums and 24 parts of feminine genders
Serum OD450 < critical value (0.699), then the sensibility for assessing this method is 91.6% (22/24) (Fig. 8).
The above is only a preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications are also answered
It is considered as protection scope of the present invention.
Sequence table
<110>Sichuan Agricultural University
<120>a kind of ELISA kit for diagnosing heartworm disease
<130> MP1908394
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 113
<212> PRT
<213>artificial sequence (Artificial Sequence)
<400> 1
Met Glu Glu Lys Val Val Glu Leu Thr His Asn Trp Ser Ala Asp Gln
1 5 10 15
Trp Asp Trp Pro Leu Gln His Asn Asp Asp Val Val Lys Val Thr Asn
20 25 30
Thr Asn Asp Lys Phe Glu Val Gly Leu Asp Ala Ser Phe Phe Thr Pro
35 40 45
Lys Glu Ile Glu Val Lys Val Cys Gly Asp Asn Leu Val Ile His Cys
50 55 60
Arg His Glu Thr Arg Thr Asp Gln Tyr Gly Glu Ile Lys Arg Glu Ile
65 70 75 80
Ser Arg Thr Tyr Lys Leu Pro Ser Asp Val Asp Thr Lys Thr Leu Thr
85 90 95
Ser Asn Leu Thr Lys Arg Gly His Leu Val Ile Ala Ala Lys Lys Lys
100 105 110
Ala
Claims (9)
1. a kind of ELISA kit for diagnosing heartworm disease, which is characterized in that including being coated with the small heat shock protein of heart worm
White solid phase carrier.
2. ELISA kit according to claim 1, which is characterized in that further include ELIAS secondary antibody, cleaning solution, developing solution, envelope
Close one or more of liquid, dilution, terminate liquid.
3. ELISA kit according to claim 2, which is characterized in that the ELIAS secondary antibody is the rabbit-anti dog of HRP label
IgG。
4. ELISA kit according to claim 2, which is characterized in that the cleaning solution is PBS-T cleaning solution.
5. ELISA kit according to claim 2, which is characterized in that the developing solution is TMB developing solution.
6. ELISA kit according to claim 2, which is characterized in that the confining liquid is skim milk.
7. ELISA kit according to claim 2, which is characterized in that the dilution is PBS.
8. ELISA kit according to claim 2, which is characterized in that the terminate liquid is sulfuric acid solution.
9. ELISA kit according to claim 1, which is characterized in that the sequence of the heart worm small heat shock protein
As shown in SEQ ID NO:1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910469902.2A CN110133290B (en) | 2019-05-31 | 2019-05-31 | ELISA kit for diagnosing heartworm disease |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910469902.2A CN110133290B (en) | 2019-05-31 | 2019-05-31 | ELISA kit for diagnosing heartworm disease |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110133290A true CN110133290A (en) | 2019-08-16 |
CN110133290B CN110133290B (en) | 2021-02-26 |
Family
ID=67583274
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910469902.2A Expired - Fee Related CN110133290B (en) | 2019-05-31 | 2019-05-31 | ELISA kit for diagnosing heartworm disease |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110133290B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110988340A (en) * | 2019-11-22 | 2020-04-10 | 四川农业大学 | Application of Eimeria siei SAG8 protein |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103298485A (en) * | 2010-11-15 | 2013-09-11 | 伊利诺伊大学理事会 | Multivalent vaccine for filariasis |
-
2019
- 2019-05-31 CN CN201910469902.2A patent/CN110133290B/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103298485A (en) * | 2010-11-15 | 2013-09-11 | 伊利诺伊大学理事会 | Multivalent vaccine for filariasis |
Non-Patent Citations (4)
Title |
---|
C. DAVID LILLIBRIDGE等: "Dirofilaria immitis: Ultrastructural Localization, Molecular Characterization,and Analysis of the Expression of p27, a Small Heat Shock Protein Homolog of Nematodes", 《JOBNAME: JEP》 * |
GAJALAKSHMI DAKSHINAMOORTHY等: "Evaluation of a Multivalent Vaccine against Lymphatic Filariasis in Rhesus macaque Model", 《PLOS ONE》 * |
JAVIER GONZÁLEZ-MIGUEL,ET AL: "Identification of Dirofilariaimmitis immunoreactive proteins recognized by sera from infected cats using two-dimensional electrophoresis and mass spectrometry", 《MOLECULAR & BIOCHEMICAL PARASITOLOGY》 * |
R. MORCHÓN,ET AL: "Proteomic analysis of the somatic and surface compartments from Dirofilaria immitis adult worms", 《VETERINARY PARASITOLOGY》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110988340A (en) * | 2019-11-22 | 2020-04-10 | 四川农业大学 | Application of Eimeria siei SAG8 protein |
CN110988340B (en) * | 2019-11-22 | 2023-03-10 | 四川农业大学 | Application of Eimeria siei SAG8 protein |
Also Published As
Publication number | Publication date |
---|---|
CN110133290B (en) | 2021-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6355777B1 (en) | P43 antigen for the immunodiagnosis of canine ehrlichiosis and uses thereof | |
CN110746495A (en) | Recombinant protein E2 and application thereof | |
CN106093435B (en) | The application of Echinococcus granulosus Glutaredoxin 1 | |
KR101667122B1 (en) | Improved vaccine diagnostics | |
CN110051832A (en) | A kind of heart worm disease vaccine | |
CN113354722B (en) | Application of echinococcus granulosus Severin protein in kit for detecting cystic echinococcosis and echinococcus granulosus infection | |
CN106811470A (en) | A kind of preparation method of dog relaxation precipitinogen recombinant protein and dog relaxation precipitinogen polyclonal antibody | |
CN106018831A (en) | Marker GP50 for coenuriasis, as well as coenuriasis diagnosing kit for diagnosing coenuriasis | |
CN107478835B (en) | The application of itch mite protein tyrosine kinase and the kit of diagnosis psoroptic mange | |
CN110133290A (en) | A kind of ELISA kit diagnosing heartworm disease | |
CN110221060B (en) | Antigen for early diagnosis of haemonchus contortus infection and application thereof | |
CN108101974B (en) | Fasciola hepatica multi-epitope fusion diagnostic antigen and application and preparation method thereof | |
CN101967472A (en) | RBP4 hybridoma cell strain and preparation method and application thereof | |
CN106636149B (en) | Parabronema skrjabini serine/threonine protein kitase Pj_STPK gene cloning, prokaryotic expression method and application | |
CN106636122B (en) | Parabronema skrjabini cystatin Pj_CPI gene cloning, recombinant expression method and application | |
CN110133291A (en) | The application of heart worm small heat shock protein | |
ES2355265T3 (en) | A KIT FOR IMMUNE DETECTION OF NUROGLOBULIN LINKED TO ENZYME AND USE OF THE SAME. | |
CN108893476A (en) | Babesiamicrofti 2D97 antigen protein and its application | |
CN108982849A (en) | The application of EG-TPx and the kit for diagnosing domestic animal echinococcosis granulosa | |
CN110196337B (en) | ELISA kit for diagnosing cercaria cerebralis | |
JP4321881B2 (en) | In vitro animal or attack model for protective immunity assay against parasite and vaccine showing protective action in the method | |
MX2010009516A (en) | Novel sequences of brachyspira, immunogenic compositions, methods for preparation and use thereof. | |
CN101967465B (en) | Retinol binding protein (RBP) monoclonal antibody and hybridoma cells, preparation method and application thereof | |
CN110988340A (en) | Application of Eimeria siei SAG8 protein | |
CN110794134A (en) | Application of Eimeria siei SAG4 protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210226 |
|
CF01 | Termination of patent right due to non-payment of annual fee |